Mireille Cantarini, BSc, MB, ChB, MRCP, FFPM
Senior Medical Director, Medical Affairs, Oncology
Mireille Cantarini is Senior Medical Director, Medical Affairs, Oncology for Worldwide Clinical Trials. Her career in clinical research spans almost two decades and has seen her engaged in clinical studies around the globe, across all phases of study from first-in-human to pivotal registration studies. She is committed to the professional development of physicians within the pharmaceutical industry and has a history of peer-reviewed scientific publications going back to 1987.
ABOUT MIREILLE CANTARINI, BSc, MB, ChB, MRCP, FFPM
During Dr. Cantarini’s 20 year career in clinical research, she has engaged in oncology clinical studies around the globe, across all phases of study from first-in-human to pivotal registration studies.
For example, at AstraZeneca Dr. Cantarini was a member of the Oncology Early Clinical Development team who led Phase I/IIb studies for several cancer indications throughout Europe, the US, Southeast Asia, Japan, South America, South Africa, and China.
And, she served as Executive Medical Director in the osimertinib (indication T790M-positive non-small cell lung cancer (NSCLC)) program, taking clinical development from first dose-in-human to full regulatory approvals in all major territories (FDA, EMEA, Japan, and China) in four years.
Dr. Cantarini also served as Honorary Fellow in the Department of Genomic Medicine at St Mary’s Hospital, lectures at University College London as part of the MSc in Drug Discovery and Pharma Management course, and she has contributed to publications in peer-reviewed journals, including Nature Medicine, New England Journal of Medicine, Journal of Clinical Oncology, and The Lancet Oncology.
